Advate
What Advate is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Advate
- Active substance
- octocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Takeda Manufacturing Austria AG
- Authorised in the EU since
- 2004
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Advate used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.
What is the active substance in Advate?
Advate contains octocog alfa.
Who makes Advate?
The EU marketing authorisation holder is Takeda Manufacturing Austria AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU